4-Phenyl-5-(3-dimethylamino-propyl)-8-chlor-2,3,4,5-tetrahydro-1-benzoxepin-5-ol | 47423-64-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噁庚英
• 英文名称: 4-Phenyl-5-(3-dimethylamino-propyl)-8-chlor-2,3,4,5-tetrahydro-1-benzoxepin-5-ol
• 英文别名: 8-chloro-5-[3-(dimethylamino)propyl]-4-phenyl-3,4-dihydro-2H-1-benzoxepin-5-ol
• CAS: 47423-64-3
• 化学式: C₂₁H₂₆ClNO₂
• 分子量: 359.896
• InChiKey: UWXGLCVZTPMATR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  32.7
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] BENZOCYCLOHEPTANE AND BENZOXEPINE DERIVATIVES<br/>[FR] DÉRIVÉS DE BENZOCYCLOHEPTANE ET DE BENZOXÉPINE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009133052A1

  公开（公告）日：2009-11-05

  The present invention relates to a compound of formula (I), including any stereochemically isomeric form thereof, wherein the substituents are as defined in the specification and the claims; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof; provided that the compound is other than formula (B) or a pharmaceutically acceptable salt thereof. The claimed compounds are useful for the treatment of a disease, the treatment of which is affected, mediated or facilitated by activating the GHS1A-r receptor. The invention also relates to pharmaceutical compositions thereof and processes for the preparation thereof.

  本发明涉及一种具有以下式（I）的化合物，包括其任何立体化学异构体形式，其中取代基如规范和权利要求中所定义；其N-氧化物，其药学上可接受的盐或其溶剂化合物；前提是该化合物不是式（B）或其药学上可接受的盐。所述的化合物用于治疗一种疾病，该疾病的治疗受到激活GHS1A-r受体的影响、调节或促进。本发明还涉及其药物组合物和制备方法。
• BENZOCYCLOHEPTANE AND BENZOXEPINE DERIVATIVES
  申请人：Schoentjes Bruno

  公开号：US20110046139A1

  公开（公告）日：2011-02-24

  The present invention relates to a compound of formula (I) including any stereochemically isomeric form thereof, wherein the substituents are as defined in the specification and the claims; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof; provided that the compound is other than or a pharmaceutically acceptable salt thereof. The claimed compounds are useful for the treatment of a disease, the treatment of which is affected, mediated or facilitated by activating the GHS1A-r receptor. The invention also relates to pharmaceutical compositions thereof and processes for the preparation thereof
• US8278466B2
  申请人：——

  公开号：US8278466B2

  公开（公告）日：2012-10-02
• US8703973B2
  申请人：——

  公开号：US8703973B2

  公开（公告）日：2014-04-22
• US9040725B2
  申请人：——

  公开号：US9040725B2

  公开（公告）日：2015-05-26